Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma

Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma

Despite poor response rates and dose-limiting cardiotoxicity, doxorubicin (doxo) remains the standard-of-care for patients with advanced soft tissue sarcoma. We evaluated the efficacy of two tetrapeptidic doxo prodrugs (PhAc-ALGP-Dox or CBR-049 and CBR-050) that are locally activated by enzymes expr...

Full description

Bibliographic Details
Main Authors: Britt Van Renterghem, Agnieszka Wozniak, Ludovica Tarantola, Andrea Casazza, Jasmien Wellens, Madita Nysen, Ulla Vanleeuw, Che-Jui Lee, Geert Reyns, Raf Sciot, Nele Kindt, Patrick Schöffski
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
PhAc-ALGP-Dox
tetra-drug technology
doxorubicin prodrug
soft tissue sarcoma
patient-derived xenograft
Online Access:https://www.mdpi.com/2227-9059/10/4/862

Internet

https://www.mdpi.com/2227-9059/10/4/862

Similar Items